This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Research
Consumer StaplesChina’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
Xuancheng, Anhui: the upper limit of the unified provident fund loan is 500000 yuan, and the number of talents is increased by 100000 yuan
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
A Closer Look at China’s Cloud Service Market, Guessing Who Will Succeed? [1/2]
Jun 27, 2022 05:09 PM
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Jun 27, 2022 12:24 PM